New drug may help stem cell transplant patients avoid extra immune suppression

NCT ID NCT05996627

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 34 times

Summary

This study tests whether the drug belumosudil can prevent chronic graft-versus-host disease (cGVHD) from worsening in stem cell transplant recipients. About 82 participants will receive either belumosudil or a placebo. The goal is to see if the drug delays the need for additional immune-suppressing treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

City of Hope
NOT_YET_RECRUITING

Duarte, California, 91010, United States

Contact
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

Contact
Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States

Contact
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

Contact

Conditions

The condition(s) this trial relates to.

Bronchiolitis Obliterans Syndrome chronic graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC GRAFT VERSUS HOST DISEASE